TG Therapeutics | TGTX - Interest Expense On Debt



TG Therapeutics reported $6.72M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Alaunos Therapeutics USD 0 0 Dec/2023
Amgen USD 694M 29M Jun/2025
Ardelyx USD 6.58M 2.61M Jun/2025
Arrowhead Research USD 24.38M 2.74M Jun/2025
Bayer 495M 89M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
Corcept Therapeutics 6M 6M Jun/2024
Dynavax Technologies USD 1.64M 51K Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
J&J USD 128M 9M Mar/2025
Novartis USD 289M 19M Jun/2025
PTC Therapeutics USD 30.36M 4.03M Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
TG Therapeutics USD 6.72M 4.12M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025